EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Résistance à l’immunothérapie dans le CBNPC : état des connaissances actuelles

J Ancel, M Dewolf, B Nawrocki-Raby, A Durlach, V Dalstein, A Cortot, V Dormoy, C Gilles, M Polette, G Deslée

Revue des Maladies Respiratoires · 2026-05

DOI: 10.1016/j.rmr.2026.04.002 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Revue des Maladies Respiratoires, 2026-05. Verfasst von J Ancel und 9 weiteren Autor:innen. Beteiligte Einrichtung: Inserm, P3Cell, UMR-S 1250, université de Reims Champagne-Ardenne, Reims, France; Service de pneumologie, hôpital Cabrol, CHU de Reims, Reims, France…. Die Arbeit nennt 96 Literaturangaben. Gefördert von: Amgen Foundation Inc, URCA, Aviesan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION Non-small cell lung cancer (NSCLC) remains one of the leading causes of cancer-related mortality worldwide. Immunotherapy has significantly reshaped its treatment, leading to improved survival in a subset of patients. However, failed initial response or acquired resistance may limit the long-term benefits of immunotherapy. STATE OF THE ART Resistance to immunotherapy arises from complex and multifactorial mechanisms. They include intrinsic tumor cell alterations - such as STK11 and KEAP1 mutations, antigen presentation defects, and impaired IFNγ signaling - as well as extrinsic factors related to the tumor microenvironment, including hypoxia, immunosuppressive cell infiltration, and T-cell exclusion. In response, several combination strategies have been explored: immunotherapy with chemotherapy, anti-angiogenic agents, alternative immune checkpoint inhibitors (e.g., CTLA-4, TIGIT, LAG-3), or innate immune modulators (e.g., STING, RIG-I), with encouraging early results. PERSPECTIVES Despite recent progress, current approaches remain primarily focused on the tumor and its microenvironment, often overlooking host-related factors - such as age, comorbidities, dysbiosis, and chronic inflammation - that can significantly impact immune responsiveness. More refined patient stratification, incorporating tumor, immune, and host-derived immune and non-immune biomarkers, is essential to better tailor treatments and improve outcomes. CONCLUSIONS The future of immunotherapy in NSCLC will likely be premised on a holistic understanding of tumor biology, immune dynamics, and host characteristics. Such an integrated approach is key to overcoming current limitations, enabling personalized strategies, and broadening the clinical benefit of immunotherapy to a wider patient population.

Schlagwörter

Stichwörter der Autor:innen

BiomarkersCarcinomaCarcinome bronchique non à petites cellulesDrug resistanceImmune checkpoint inhibitorsImmunotherapyImmunothérapieInhibiteurs de points de contrôle immunitairesMarqueurs biologiquesNeoplasmNon-small cell lung cancerRésistance aux médicaments antinéoplasiques

Autor:innen und Institutionen

  • Inserm, P3Cell, UMR-S 1250, université de Reims Champagne-Ardenne, Reims, France; Service de pneumologie, hôpital Cabrol, CHU de Reims, Reims, France. Electronic address: jancel@chu-reims.fr.
  • Service de pneumologie, hôpital Cabrol, CHU de Reims, Reims, France.
  • Inserm, P3Cell, UMR-S 1250, université de Reims Champagne-Ardenne, Reims, France.
  • Inserm, P3Cell, UMR-S 1250, université de Reims Champagne-Ardenne, Reims, France; Service de pathologie, CHU de Reims, pôle de biologie territoriale, Reims, France.
  • Inserm, P3Cell, UMR-S 1250, université de Reims Champagne-Ardenne, Reims, France; Département d'oncologie moléculaire, CHU de Reims, pôle de biologie territoriale, Reims, France.
  • Département d'oncologie thoracique, centre hospitalier universitaire de Lille, Centre national de la recherche scientifique, Inserm, Institut Pasteur de Lille, UMR9020-U1277-CANTHER, Lille, France.

Förderung

  • Amgen Foundation Inc
  • URCA
  • Aviesan

Zitieren

APA

Ancel, J., Dewolf, M., Nawrocki-Raby, B., Durlach, A., Dalstein, V., Cortot, A., Dormoy, V., Gilles, C., Polette, M., & Deslée, G. (2026). Résistance à l’immunothérapie dans le CBNPC : état des connaissances actuelles. Revue des Maladies Respiratoires. https://doi.org/10.1016/j.rmr.2026.04.002

Vancouver

Ancel J, Dewolf M, Nawrocki-Raby B, Durlach A, Dalstein V, Cortot A, et al. Résistance à l’immunothérapie dans le CBNPC : état des connaissances actuelles. Revue des Maladies Respiratoires. 2026. doi:10.1016/j.rmr.2026.04.002

BibTeX
@article{Ancel2026,
  author = {Ancel, J and Dewolf, M and Nawrocki-Raby, B and Durlach, A and Dalstein, V and Cortot, A and Dormoy, V and Gilles, C and Polette, M and Deslée, G},
  title = {Résistance à l’immunothérapie dans le CBNPC : état des connaissances actuelles},
  journal = {Revue des Maladies Respiratoires},
  year = {2026},
  doi = {10.1016/j.rmr.2026.04.002}
}
Kostenlos starten →